Skip to content
Search
Please enter at least 3 characters.

Latest Stories

NHS England turns to AI to ease pressures on A&Es

NHS England turns to AI to ease pressures on A&Es

This new approach is expected to prevent 4,500 unnecessary A&E attendances over the next two years 

NHS England is rolling out a range of tech and data solutions, including an artificial intelligence (AI) system, across the health service to tackle winter pressures.


The AI system will be used to identify patients at risk of hospital admission so community NHS teams can get to them first and reduce pressures on A&E departments.

On a trial basis, four GP practices in Somerset have started using the innovative technology which can highlight registered patients with complex health needs.

Health coaches, nurses, or GPs will then reach out to the people most at risk, and provide them with a range of preventive care such as monitoring, food parcels, cleaning, shopping, as well as escalating care to specialist doctors.

For example, AI linked to electronic sensors on kettles and fridges is helping spot changes in patients’ eating and drinking habits in Buckinghamshire.

Patients with health needs are then contacted by a non-clinical Onward Care team, which is able to solve 95 per cent of their issues or escalate anything clinical.

However, patients can choose whether they want to benefit from these local, practical measures or not.

NHS chief executive, Amanda Pritchard, commented that NHS staff across the country are innovating every step of the way, maximising the use of “the latest technology and AI” to help patients and reduce the number of “avoidable” A&E attendances.

In some areas of Birmingham, the NHS is using an algorithm to predict the top five per cent at risk of potential hospital attendances or admissions.

Health staff reach out to these people and offer social care assessments, medication reviews or other social prescribing measures to avoid A&E admissions.

The scheme is expected to prevent 4,500 unnecessary A&E attendances, 17,000 overnight hospital stays, and free up 23,000 GP appointments over the next two years.

The new innovations are part of the winter preparations taken up by the NHS to ease the pressure from its staff across the country, as the latest data revealed that A&E departments and ambulance services experienced the busiest October this year.

Pritchard added that this suite of tech and data solutions are an “extra and welcome addition to our winter toolkit, with more call handlers and more beds already in place.”

The NHS is also running its annual 111 campaign across catch-up TV, radio, social media, reminding people to continue to use NHS 111 services when they need “urgent, but not life-threatening, medical advice.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less